676 results on '"Foroni L"'
Search Results
2. Complexité de la gestion des médicaments relevant du dispositif pérenne post-ATU dans un centre hospitalier universitaire
3. Implication du préparateur en pharmacie hospitalière dans le déploiement de la conciliation des traitements médicamenteux en France : représentations et engagement des préparateurs
4. The Detection of Minimal Residual Disease in Acute Leukemia
5. Réflexion pluri-professionnelle pour la promotion du bon usage des sangsues en établissement de santé
6. Audits des points de stockage de médicaments en unités de soins : retour d’expérience du CHU Grenoble-Alpes
7. Comité de retour d’expérience (CREX) d’une pharmacie à usage intérieur : bilan de fonctionnement et suivi du devenir des actions correctives
8. Compliance with carbapenem guidelines in a university hospital
9. Étude in vitro de la durée d’écoulement de solutions antibiotiques préparées dans des diffuseurs portables élastomériques : effet du stockage au froid pendant trois à sept jours
10. Impact of systemic antifungal therapy on the detection of Candida species in blood cultures in clinical cases of candidemia
11. P713: REAL-WORLD MANAGEMENT OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML): FIRST ANALYSIS FROM THE UK NATIONAL REGISTRY FOR CML
12. P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE
13. A prospective multicentre study of the demographic, molecular and clinical landscape of myeloproliferative neoplasm in a developing country: 330
14. T cell subsets do not alter on decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: Data from the DESTINY trial: 290
15. De-escalation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia patients with excellent molecular responses: Initial safety results from the DESTINY trial: 13
16. Dysfunctional Vasa Vasorum in Diabetic Peripheral Artery Obstructive Disease with Critical Lower Limb Ischaemia
17. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
18. Le pharmacien a-t-il une place au sein de l’unité de soins ? Expérience du centre hospitalier universitaire de Grenoble: A pharmacist inside the care unit: Current data and experience of the Grenoble university hospital
19. DETECTION OF BRAF P.VAL600GLU MUTATION IN THYROID NODULES USING SANGER, PYROSEQUENCING AND NEXT GENERATION SEQUENCING: FP11-3
20. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
21. SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed chronic myeloid leukaemia - 2 year follow up: 27
22. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR
23. Mise en assurance qualité de la radiopharmacie du centre hospitalier universitaire de Grenoble : apport d’un logiciel informatique
24. La sécurisation du circuit du médicament dans les établissements de santé : données actuelles et expérience du centre hospitalier universitaire de Grenoble
25. The Rhombotin Family of Cysteine-Rich LIM-Domain Oncogenes: Distinct Members are Involved in T-Cell Translocations to Human Chromosomes 11p15 and 11p13
26. Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT
27. Dual Glutathione-S-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia
28. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
29. Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity
30. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib
31. Analysis of BCR–ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype
32. SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML: 1
33. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
34. Genetically identical twin transplantation for chronic lymphocytic leukemia
35. The “in situ” expression of Human Leukocyte Antigen Class I antigens is not altered by cryopreservation in human arterial allografts
36. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
37. Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936
38. Revue de pertinence des prescriptions des nouveaux antifongiques systémiques dans un hôpital universitaire
39. Prospective assessment of fluoroquinolone use in a teaching hospital
40. Donor KIR2DS2/DL2 genotype status is associated with an increased incidence of severe acute graft-versus-host disease following myeloablative haematopoeitic stem cell transplantation: O160
41. Deletion analysis of chromosome 13q14.3 and characterisation of an alternative splice form of LEU1 in B cell chronic lymphocytic leukemia
42. Heterogeneity of VH–JH gene rearrangement patterns: an insight into the biology of B cell precursor ALL
43. Conformité des prescriptions d'antibiotiques dans les infections urinaires de l'adulte en milieu hospitalier
44. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia
45. Staging criteria based on maximal disease stage pre-transplant predicts the outcome of allogeneic stem cell transplantation for chronic myeloid leukaemia in the imatinib era: P1155
46. Chronic phase CML patients on tyrosine kinase inhibitors have a normal cellular immune response against influenza but an impaired IgM humoral response against pneumococcus after vaccination: implications for immunotherapy: P1153
47. Nerve transfers for acute flaccid myelitis: a case series
48. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
49. FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission
50. EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib: 45
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.